Below are the three companies in the Pharmaceuticals industry with the lowest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Akorn Inc ranks lowest with a EBITDA growth of -2.2%. Phibro Animal-A is next with a EBITDA growth of 4.0%. Depomed Inc ranks third lowest with a EBITDA growth of 5.1%.

Bristol-Myer Sqb follows with a EBITDA growth of 11.4%, and Sucampo Pha-Cl A rounds out the bottom five with a EBITDA growth of 14.5%.

SmarTrend recommended that its subscribers protect gains by selling shares of Depomed Inc on October 28th, 2016 by issuing a Downtrend alert when the shares were trading at $22.73. Since that call, shares of Depomed Inc have fallen 72.2%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.